Novo Nordisk, and Merck; and has received research/grant support from Eli Lilly, Amylin, Novo Nordisk,Merck, and GlaxoSmithKline. M.C.R. has received honoraria/consulting fees from Amylin and Amylin/Lilly.J.R. has served on advisory boards for and has received honoraria/consulting fees from Pﬁzer, Sanoﬁ-Aventis,Novo Nordisk, GlaxoSmithKline, Takeda, Centocor, Johnson & Johnson, and Amylin and has received grantsupport from Merck, Pﬁzer, Sanoﬁ-Aventis, Novo Nordisk, Eli Lilly, GlaxoSmithKline, Takeda, Novartis,AstraZeneca, Amylin, Sankyo, and MannKind. Abbreviations: AUC, area under the curve; GLP-1, glucagon-like peptide 1; ITT, intent to treat. A table elsewhere in this issue shows conventional and Syste `me International (SI) units and conversion factors for many substances. © 2005 by the American Diabetes Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby